Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors

BackgroundRenin has become an attractive target in controlling hypertension because of the high specificity towards its only substrate, angiotensinogen. The conversion of angiotensinogen to angiotensin I is the first and rate-limiting step of renin-angiotensin system and thus designing inhibitors to block this step is focused in this study.MethodsLigand-based quantitative pharmacophore modeling methodology was used in identifying the important molecular chemical features present in the set of already known active compounds and the missing features from the set of inactive compounds. A training set containing 18 compounds including active and inactive compounds with a substantial degree of diversity was used in developing the pharmacophore models. A test set containing 93 compounds, Fischer randomization, and leave-one-out methods were used in the validation of the pharmacophore model. Database screening was performed using the best pharmacophore model as a 3D structural query. Molecular docking and density functional theory calculations were used to select the hit compounds with strong molecular interactions and favorable electronic features.ResultsThe best quantitative pharmacophore model selected was made of one hydrophobic, one hydrogen bond donor, and two hydrogen bond acceptor features with high a correlation value of 0.944. Upon validation using an external test set of 93 compounds, Fischer randomization, and leave-one-out methods, this model was used in database screening to identify chemical compounds containing the identified pharmacophoric features. Molecular docking and density functional theory studies have confirmed that the identified hits possess the essential binding characteristics and electronic properties of potent inhibitors.ConclusionA quantitative pharmacophore model of predictive ability was developed with essential molecular features of a potent renin inhibitor. Using this pharmacophore model, two potential inhibitory leads were identified to be used in designing novel and future renin inhibitors as antihypertensive drugs.

[1]  W Patrick Walters,et al.  Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.

[2]  K. Nakao,et al.  Molecular cloning of a novel mouse aspartic protease‐like protein that is expressed abundantly in the kidney , 1997, FEBS letters.

[3]  A. Gradman,et al.  Current concepts: renin inhibition in the treatment of hypertension. , 2008, Current opinion in pharmacology.

[4]  S. Durdağı,et al.  Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. , 2009, European journal of medicinal chemistry.

[5]  W. Watt,et al.  Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues. , 1986, Journal of medicinal chemistry.

[6]  Thangapandian Sundarapandian,et al.  Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery , 2010 .

[7]  Kavitha Bharatham,et al.  Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. , 2007, Journal of molecular graphics & modelling.

[8]  J. Staessen,et al.  Oral renin inhibitors , 2006, The Lancet.

[9]  Steven L. Dixon,et al.  Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..

[10]  Hans-Dieter Höltje,et al.  Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists. , 2002, Molecular pharmacology.

[11]  Y. Kurogi,et al.  Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.

[12]  A. Ben Wagner,et al.  SciFinder Scholar 2006: An Empirical Analysis of Research Topic Query Processing , 2006, J. Chem. Inf. Model..

[13]  C. Oefner,et al.  Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site. , 1999, Bioorganic & medicinal chemistry letters.

[14]  Serdar Durdagi,et al.  Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. , 2010, Journal of molecular graphics & modelling.

[15]  Sugunadevi Sakkiah,et al.  Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. , 2011, European journal of medicinal chemistry.

[16]  Wei Li,et al.  Investigation of binding features: Effects on the interaction between CYP2A6 and inhibitors , 2010, J. Comput. Chem..

[17]  A. Gradman,et al.  Renin inhibition in hypertension. , 2008, Journal of the American College of Cardiology.

[18]  L. Prade,et al.  Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. , 2009, Journal of medicinal chemistry.

[19]  R. Jiao,et al.  Anti-hypertensive nutraceuticals and functional foods. , 2009, Journal of agricultural and food chemistry.

[20]  N. Hollenberg,et al.  Renin inhibition: what are the therapeutic opportunities? , 2005, Journal of the American Society of Nephrology : JASN.

[21]  Jianpeng Ma,et al.  Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands , 2008, Proteins.

[22]  Kenneth M Merz,et al.  Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. , 2003, Journal of medicinal chemistry.

[23]  N. Powell,et al.  Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[24]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[25]  The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin. , 2009, Bioorganic & medicinal chemistry letters.

[26]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[27]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[28]  S. Vadivelan,et al.  Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies. , 2009, European journal of medicinal chemistry.

[29]  M. Neves,et al.  An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. , 2009, European journal of medicinal chemistry.

[30]  S. Sakkiah,et al.  Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors. , 2011, European journal of medicinal chemistry.

[31]  R. Sarma,et al.  Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. , 2008, European journal of medicinal chemistry.

[32]  J. Pople,et al.  Self-consistent molecular orbital methods. 21. Small split-valence basis sets for first-row elements , 2002 .

[33]  Sugunadevi Sakkiah,et al.  Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. , 2010, Journal of molecular graphics & modelling.

[34]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[35]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[36]  Nilesh R. Tawari,et al.  Pharmacophore mapping and electronic feature analysis for a series of nitroaromatic compounds with antitubercular activity , 2009, J. Comput. Chem..

[37]  A. Becke A New Mixing of Hartree-Fock and Local Density-Functional Theories , 1993 .

[38]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[39]  Om Silakari,et al.  Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. , 2010, European journal of medicinal chemistry.

[40]  Maurizio Fermeglia,et al.  Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. , 2009, Journal of medicinal chemistry.

[41]  Thierry Langer,et al.  Pharmacophore Modeling and in Silico Screening for New P450 19 (Aromatase) Inhibitors , 2006, J. Chem. Inf. Model..

[42]  Mark S. Gordon,et al.  Self-consistent molecular-orbital methods. 22. Small split-valence basis sets for second-row elements , 1980 .

[43]  Keun Woo Lee,et al.  Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase , 2011, J. Chem. Inf. Model..

[44]  A. Boucekkine,et al.  DFT study of conjugated biheterocyclic oligomers exhibiting a very low HOMO–LUMO energy gap , 2004 .

[45]  N. Cohen,et al.  Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. , 2007, Chemical biology & drug design.

[46]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[47]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[48]  S. Sakkiah,et al.  Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies. , 2010, European journal of medicinal chemistry.